• Login
  • Register
Nairametrics
  • Home
  • Exclusives
    • Recapitalization
      • Access Holdings Offer
      • Fidelity Bank Offer
      • GTCO Offer
      • Zenith Bank Offer
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Nairalytics
  • Economy
    • Business News
    • Budget
    • Public Debt
    • Tax
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Public Offer & Right Issues
      • Stock Market News
    • Fixed Income
    • Funds Management
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Market Views
    • Op-Eds
    • Research Analysis
  • Home
  • Exclusives
    • Recapitalization
      • Access Holdings Offer
      • Fidelity Bank Offer
      • GTCO Offer
      • Zenith Bank Offer
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Nairalytics
  • Economy
    • Business News
    • Budget
    • Public Debt
    • Tax
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Public Offer & Right Issues
      • Stock Market News
    • Fixed Income
    • Funds Management
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Market Views
    • Op-Eds
    • Research Analysis
Nairametrics
Home Business News Business

Nigeria, others to receive first-ever HIV generic drug for babies in the first half of 2021

Adeyemi Adebayo by Adeyemi Adebayo
December 2, 2020
in Business
Nigeria, others to receive first-ever HIV generic drug for babies in the first half of 2021
Share on FacebookShare on TwitterShare on Linkedin

Nigeria and six other African countries will receive the first-ever HIV generic drug for babies in the first half of 2021.

This is according to UNITAID – global health initiative that works with partners to bring about innovations to prevent, diagnose, and treat major diseases in low-and middle-income countries, with an emphasis on tuberculosis, malaria, and HIV/AIDS, and its deadly co-infections.

UNITAID noted that the drug, a strawberry-flavoured tablet, is the first generic pediatric version of a key anti-retroviral available, even for babies, and will be rolled out in African countries in 2021.

MoreStories

Trump orders “powerful and deadly” US. strike on ISIS camp in Northwest Nigeria

Trump orders “powerful and deadly” US. strike on ISIS camp in Northwest Nigeria

December 26, 2025
LIRS seals Shoprite outlet in Lekki over tax non-compliance 

LIRS seals Shoprite outlet in Lekki over tax non-compliance 

November 12, 2025

READ: COVID-19: NCDC issues travel advisory for the yuletide season

What you should know

  • According to UNITAID, about 1.7 million children worldwide live with HIV, but only half receive any treatment – often hard to administer due to the bitter taste or incorrectly dosed by crushing adult pills.
  • About 100,000 children die of AIDS annually.
  • The first-line HIV treatment is recommended by the World Health Organization (WHO) from the age of four weeks and 3 kilos (6.6 pounds), but it had been out of reach for babies because of the lack of appropriate formulations.
  • UNITAID and the Clinton Health Access Initiative have reached a pricing agreement with the generic drug makers Viatris and Macleods for the dispersible pediatric formulation of dolutegravir (DTG).

In this context, UNITAID maintained “the estimated cost for combination therapy will now be some $120 for a child’s annual treatment, against $480 currently, making it a ‘game-changer’ for poorer countries.”

READ: Covid-19: Unilever Nigeria suffers 40% revenue loss

What they are saying

UNITAID spokesman, Herve Verhoosel, told Geneva news briefing that, “For many of those children, the HIV virus is not suppressed due in part to lack of availability of effective drugs that are palatable and properly adapted for them.”

According to Verhoosel, “Benin, Kenya, Malawi, Nigeria, Uganda and Zimbabwe are due to receive the first tablets in the first half of 2021.”

READ: Nigeria’s inflation rate to moderate by first half of next year


Add Nairametrics on Google News
Follow us for Breaking News and Market Intelligence.
Tags: HIV generic drugNigeria NewsUNITAID
Adeyemi Adebayo

Adeyemi Adebayo

Adeyemi holds a PhD in Accounting Sciences. He has worked in the Educational Sector and as an Independent Consultant.

Next Post
Lagos state imposes 24-hour curfew, as hoodlums hijack #EndSARS protest, Social clubs, recreational centres to reopen August 14, Lagos International Trade Fair to get permanent site soon, Sanwo-Olu vows , Lagos State discloses road expansion plans in an effort to combat traffic, Lagos State cracking down on Uber, Bolt, Ocar a week after Okada, Keke Napep ban , LASG increases health workers’ allowances, commissions local production of face masks

Lagos to launch new mini buses, to phase out 'Okada', 'Marwa'

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

rabafast
rabafast

nairametrics








DUNS

Follow us on social media:

  • HOME
  • ABOUT NAIRAMETRICS
  • CONTACT US
  • DISCLAIMER
  • ADs DISCLAIMER
  • COPYRIGHT INFRINGEMENT

© 2026 Nairametrics

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Social Media Auto Publish Powered By : XYZScripts.com
No Result
View All Result
  • Home
  • Exclusives
    • Recapitalization
      • Access Holdings Offer
      • Fidelity Bank Offer
      • GTCO Offer
      • Zenith Bank Offer
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Nairalytics
  • Economy
    • Business News
    • Budget
    • Public Debt
    • Tax
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Public Offer & Right Issues
      • Stock Market News
    • Fixed Income
    • Funds Management
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Market Views
    • Op-Eds
    • Research Analysis
  • Login
  • Sign Up

© 2026 Nairametrics